LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,690
تعداد دریافت فایل اصل مقاله11,291,481
Nekooeian, Ali Akbar, Rasti Pour, Amin, Dehghani, Farzaneh, Mashghoolozekr, Elaheh, Esmaeilpour, Tahereh. (1400). Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension. سامانه مدیریت نشریات علمی, 46(3), 169-179. doi: 10.30476/ijms.2020.81948.0
Ali Akbar Nekooeian; Amin Rasti Pour; Farzaneh Dehghani; Elaheh Mashghoolozekr; Tahereh Esmaeilpour. "Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension". سامانه مدیریت نشریات علمی, 46, 3, 1400, 169-179. doi: 10.30476/ijms.2020.81948.0
Nekooeian, Ali Akbar, Rasti Pour, Amin, Dehghani, Farzaneh, Mashghoolozekr, Elaheh, Esmaeilpour, Tahereh. (1400). 'Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension', سامانه مدیریت نشریات علمی, 46(3), pp. 169-179. doi: 10.30476/ijms.2020.81948.0
Nekooeian, Ali Akbar, Rasti Pour, Amin, Dehghani, Farzaneh, Mashghoolozekr, Elaheh, Esmaeilpour, Tahereh. Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension. سامانه مدیریت نشریات علمی, 1400; 46(3): 169-179. doi: 10.30476/ijms.2020.81948.0

Effects of Captopril and Losartan on Cardiac Stereology in Rats with Renovascular Hypertension

Iranian Journal of Medical Sciences
مقاله 3، دوره 46، شماره 3، مرداد 2021، صفحه 169-179    اصل مقاله (1.38 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2020.81948.0
نویسندگان
Ali Akbar Nekooeian1؛ Amin Rasti Pour2؛ Farzaneh Dehghani2، 3؛ Elaheh Mashghoolozekr1؛ Tahereh Esmaeilpour* 2
1Cardiovascular Pharmacology Research Lab, Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Anatomy, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Histomorphometry and Stereology Research center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Captopril, an angiotensin-converting enzyme inhibitor, and losartan, an angiotensin II receptor blocker, are used for the treatment of hypertension, but their effects on cardiac stereology are unknown. This study, therefore, aimed to examine their effects on cardiac stereology in rats with renovascular hypertension.
Methods: This study was conducted at Histomorphometry and Stereology Research Centre, and Cardiovascular Pharmacology Research Lab, Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, in August 2015 to August 2016. Fourty-eight rats were allocated to six groups (n=8 per each group): a sham group, which received a vehicle (distilled water) and five renal artery-clipped groups, which received the vehicle, captopril (50 or 100 mg/kg/day), or losartan (25 or 50 mg/kg/day). After four weeks, the animals’ systolic blood pressures (mm Hg) were measured, and the total volumes of their heart, myocardium, endocardium, matrix, and myocardial vessels (mm3), as well as the number of their cardiomyocytes, and Purkinje fibers were determined. Data were analyzed using one-way analysis of variance (ANOVA) followed by least significant difference (LSD) test. P value of equal to or less than 0.05 was considered significant.
Results: The renal artery-clipped rats receiving the vehicle had a significantly higher systolic blood pressure (p <0.001); heart weight (g) (p <0.001); and total volume of the heart (p <0.001), myocardium (P=0.020), endocardium (P=0.009), and myocardial vessels (P=0.008); as well as a significantly lower number of cardiomyocytes (P=0.010) and Purkinje cells (P=0.005), than did the rats in the sham group. The renal artery-clipped rats receiving captopril or losartan had a significantly lower systolic blood pressure (p <0.001), heart weight (P=0.007), and total volume of the heart (p <0.001), myocardium (p <0.001), endocardium (P=0.027), and myocardial vessels (P=0.004) than did the renal artery-clipped rats receiving the vehicle. Neither captopril nor losartan prevented a reduction in the number of Purkinje cells, but captopril at the higher dose attenuated cardiomyocyte loss (P=0.010).
Conclusion: Captopril and losartan lowered the systolic blood pressure and cardiac hypertrophy but failed to prevent Purkinje cell loss. Captopril only at the higher dose prevented cardiomyocyte loss. Captopril exerted a greater inhibitory effect on cardiac stereology, which warrants further research.
کلیدواژه‌ها
Heart؛ Hypertension؛ Renovascular؛ Captopril؛ Losartan
سایر فایل های مرتبط با مقاله
مراجع
  1. Islam SM, Mainuddin A, Islam MS, Karim MA, Mou SZ, Arefin S, et al. Prevalence of risk factors for hypertension: A cross-sectional study in an urban area of Bangladesh. Glob Cardiol Sci Pract. 2015;2015:43. doi: 10.5339/gcsp.2015.43. PubMed PMID: 26779518; PubMed Central PMCID: PMCPMC4710872.
  2. Lackland DT, Weber MA. Global burden of cardiovascular disease and stroke: hypertension at the core. Can J Cardiol. 2015;31:569-71. doi: 10.1016/j.cjca.2015.01.009. PubMed PMID: 25795106.
  3. Fernandes-Santos C, Mendonça LdS, Mandarim-de-Lacerda CA. Beneficial effects of angiotensin II AT1 blocker on cardiovascular adverse remodeling due to nitric oxide synthesis blockade. Int J Morphol. 2006;24:309-18. doi: 10.4067/S0717-95022006000400003.
  4. Guo X, Fan C, Tian L, Liu Y, Wang H, Zhao S, et al. The clinical features, outcomes and genetic characteristics of hypertrophic cardiomyopathy patients with severe right ventricular hypertrophy. PLoS One. 2017;12:e0174118. doi: 10.1371/journal.pone.0174118. PubMed PMID: 28323875; PubMed Central PMCID: PMCPMC5360271.
  5. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res. 2010;61:269-80. doi: 10.1016/j.phrs.2009.11.012. PubMed PMID: 19969085.
  6. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart. 2003;89:1104-9. doi: 10.1136/heart.89.9.1104. PubMed PMID: 12923045; PubMed Central PMCID: PMCPMC1767863.
  7. Piek A, de Boer RA, Sillje HH. The fibrosis-cell death axis in heart failure. Heart Fail Rev. 2016;21:199-211. doi: 10.1007/s10741-016-9536-9. PubMed PMID: 26883434; PubMed Central PMCID: PMCPMC4762920.
  8. Kaur M, Rana A, Kumar S. Induction of hypertension by various animal models. 2011;1:335-40.
  9. Castro MM, Tanus-Santos JE, Gerlach RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res. 2011;64:567-72. doi: 10.1016/j.phrs.2011.04.002. PubMed PMID: 21514386.
  10. Fernandes-Santos C, de Souza Mendonca L, Mandarim-de-Lacerda CA. Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. Heart Vessels. 2009;24:219-27. doi: 10.1007/s00380-008-1104-3. PubMed PMID: 19466524.
  11. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1847-60. doi: 10.1152/ajpheart.00434.2006. PubMed PMID: 17158653.
  12. Bernatova I, Pechanova O, Simko F. Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol. 1999;84:1095-105. doi: 10.1111/j.1469-445X.1999.01890.x. PubMed PMID: 10564706.
  13. Castro-Moreno P, Pardo JP, Hernandez-Munoz R, Lopez-Guerrero JJ, Del Valle-Mondragon L, Pastelin-Hernandez G, et al. Captopril avoids hypertension, the increase in plasma angiotensin II but increases angiotensin 1-7 and angiotensin II-induced perfusion pressure in isolated kidney in SHR. Auton Autacoid Pharmacol. 2012;32:61-9. doi: 10.1111/aap.12001. PubMed PMID: 22994939.
  14. Rocha WA, Lunz W, Baldo MP, Pimentel EB, Dantas EM, Rodrigues SL, et al. Kinetics of cardiac and vascular remodeling by spontaneously hypertensive rats after discontinuation of long-term captopril treatment. Braz J Med Biol Res. 2010;43:390-6. doi: 10.1590/s0100-879x2010007500023. PubMed PMID: 20379690.
  15. Burnier M, Wuerzner G. Pharmacokinetic evaluation of losartan. Expert Opin Drug Metab Toxicol. 2011;7:643-9. doi: 10.1517/17425255.2011.570333. PubMed PMID: 21417956.
  16. Koprdova R, Cebova M, Kristek F. Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats. Physiol Res. 2009;58:327-35. PubMed PMID: 18637711.
  17. Xu F, Mao C, Hu Y, Rui C, Xu Z, Zhang L. Cardiovascular effects of losartan and its relevant clinical application. Curr Med Chem. 2009;16:3841-57. doi: 10.2174/092986709789178046. PubMed PMID: 19747137; PubMed Central PMCID: PMCPMC2888651.
  18. Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals. Ottawa: Canadian Council on Animal Care; 1993.
  19. Nekooeian A, Mashhoodi T. Solid plexiglass clips to induce reproducible renal hypertension in the rat. Indian Journal of Pharmacology. 2007;39:25. doi: 10.4103/0253-7613.30758.
  20. Mozafari M, Nekooeian AA, Panjeshahin MR, Zare HR. The effects of resveratrol in rats with simultaneous type 2 diabetes and renal hypertension: a study of antihypertensive mechanisms. Iran J Med Sci. 2015;40:152-60. PubMed PMID: 25821295; PubMed Central PMCID: PMCPMC4359935.
  21. Scherle W. A simple method for volumetry of organs in quantitative stereology. Mikroskopie. 1970;26:57-60. PubMed PMID: 5530651.
  22. Moghadam A, Khozani TT, Mafi A, Namavar MR, Dehghani F. Effects of Platelet-Rich Plasma on Kidney Regeneration in Gentamicin-Induced Nephrotoxicity. J Korean Med Sci. 2017;32:13-21. doi: 10.3346/jkms.2017.32.1.13. PubMed PMID: 27914126; PubMed Central PMCID: PMCPMC5143284.
  23. Dehghani F, Sotoude N, Bordbar H, Panjeshahin MR, Karbalay-Doust S. The use of platelet-rich plasma (PRP) to improve structural impairment of rat testis induced by busulfan. Platelets. 2019;30:513-20. doi: 10.1080/09537104.2018.1478400. PubMed PMID: 29883240.
  24. Badyal D, Lata H, Dadhich A. Animal models of hypertension and effect of drugs. Indian Journal of pharmacology. 2003;35:349-62.
  25. Haydari MR, Panjeshahin MR, Mashghoolozekr E, Nekooeian AA. Antihypertensive Effects of Hydroalcoholic Extract of Crataegus Azarolus Subspecies Aronia Fruit in Rats with Renovascular Hypertension: An Experimental Mechanistic Study. Iran J Med Sci. 2017;42:266-74. PubMed PMID: 28533575; PubMed Central PMCID: PMCPMC5429495.
  26. Rizzi E, Ceron CS, Guimaraes DA, Prado CM, Rossi MA, Gerlach RF, et al. Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-beta in renovascular hypertension-induced cardiac hypertrophy. Exp Mol Pathol. 2013;94:1-9. doi: 10.1016/j.yexmp.2012.10.010. PubMed PMID: 23073243.
  27. Soltani Hekmat A, Najafipour H, Nekooian AA, Esmaeli-Mahani S, Javanmardi K. Cardiovascular responses to apelin in two-kidney-one-clip hypertensive rats and its receptor expression in ischemic and non-ischemic kidneys. Regul Pept. 2011;172:62-8. doi: 10.1016/j.regpep.2011.08.010. PubMed PMID: 21911011.
  28. Goodman LS. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996.
  29. Ritchie RH, Delbridge LM. Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect? Clin Exp Pharmacol Physiol. 2006;33:159-66. doi: 10.1111/j.1440-1681.2006.04342.x. PubMed PMID: 16445716.
  30. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551-71. doi: 10.1146/annurev.physiol.59.1.551. PubMed PMID: 9074777.
  31. Takai S, Jin D, Sakaguchi M, Miyazaki M. Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res. 2004;27:213-9. doi: 10.1291/hypres.27.213. PubMed PMID: 15080380.
  32. Buzello M, Boehm C, Orth S, Fischer B, Ehmke H, Ritz E, et al. Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension. Virchows Arch. 2003;442:364-71. doi: 10.1007/s00428-003-0775-5. PubMed PMID: 12684765.
  33. Gonzalez A, Lopez B, Ravassa S, Querejeta R, Larman M, Diez J, et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension. 2002;39:75-80. doi: 10.1161/hy0102.100788. PubMed PMID: 11799082.
  34. Wiener J, Giacomelli F, Loud AV, Anversa P. Morphometry of cardiac hypertrophy induced by experimental renal hypertension. Am J Cardiol. 1979;44:919-29. doi: 10.1016/0002-9149(79)90223-6. PubMed PMID: 158965.
  35. Ishizu T, Seo Y, Kameda Y, Kawamura R, Kimura T, Shimojo N, et al. Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease. Hypertension. 2014;63:500-6. doi: 10.1161/HYPERTENSIONAHA.113.02149. PubMed PMID: 24396022.
  36. Schnabel PA, Richter J, Schmiedl A, Ramsauer B, Bartels U, Gebhard MM, et al. The ultrastructural effects of global ischaemia on Purkinje fibres compared with working myocardium: a qualitative and morphometric investigation on the canine heart. Virchows Arch A Pathol Anat Histopathol. 1991;418:17-25. doi: 10.1007/BF01600240. PubMed PMID: 1899164.
  37. Ideker RE, Kong W, Pogwizd S. Purkinje fibers and arrhythmias. Pacing Clin Electrophysiol. 2009;32:283-5. doi: 10.1111/j.1540-8159.2008.02232.x. PubMed PMID: 19272054; PubMed Central PMCID: PMCPMC2743071.
  38. Soleimani AR, Akbari H, Soleimani S, Beladi Mousavi SS, Tamadon MR. Effect of sour tea (Lipicom) pill versus captopril on the treatment of hypertension. J Renal Inj Prev. 2015;4:73-9. doi: 10.12861/jrip.2015.15. PubMed PMID: 26468478; PubMed Central PMCID: PMCPMC4594217.
  39. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-324. doi: 10.1161/HYP.0000000000000066. PubMed PMID: 29133354.
  40. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. doi: 10.1093/eurheartj/ehy339. PubMed PMID: 30165516.
  41. Mulrow PJ. Angiotensin II and aldosterone regulation. Regulatory peptides. 1999;80:27-32. doi: 10.1016/S0167-0115(99)00004-X.
  42. Buharalioglu CK, Song CY, Yaghini FA, Ghafoor HU, Motiwala M, Adris T, et al. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol. 2011;301:H1043-55. doi: 10.1152/ajpheart.01018.2010. PubMed PMID: 21642504; PubMed Central PMCID: PMCPMC3191073.
  43. Nagano M. Inhibitory effect of captopril on cell degeneration and growth. Exp Clin Cardiol. 2006;11:195-7. PubMed PMID: 18651031; PubMed Central PMCID: PMCPMC2276157.
  44. Li Z, Bing OH, Long X, Robinson KG, Lakatta EG. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol. 1997;272:H2313-9. doi: 10.1152/ajpheart.1997.272.5.H2313. PubMed PMID: 9176300.
آمار
تعداد مشاهده مقاله: 4,775
تعداد دریافت فایل اصل مقاله: 2,911


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب